Blogs

Blogs

Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis

Resmetirom Reduces Liver, CV Risk Factors in NASH With Cirrhosis

WASHINGTON — In patients with cirrhosis associated with non-alcoholic steatohepatitis (NASH), 1 year of treatment with the investigational oral thyromimetic agent resmetirom (MGL-3196) was safe and effective at lowering markers of both cardiovascular risk and NASH fibrosis, new research has found. Two cohorts comprising a total of 180 patients with well-compensated NASH cirrhosis enrolled in […]

Learn More
Have you tested for Hepatitis B

Have you tested for Hepatitis B

Hepatitis B is a virus that infects the liver. Most infected individuals have no symptoms till late in the course of the disease. Hepatitis B affects an estimated 250 million people worldwide and results in about 800000 deaths every year. The prevalence of hepatitis B infection is 1-5% worldwide. Areas of high prevalence include Southeast […]

Learn More
Whatsapp Now Get Clinic or Online Consultation